Diese Website verwendet Cookies, damit wir dir die bestmögliche Benutzererfahrung bieten können. Cookie-Informationen werden in deinem Browser gespeichert und führen Funktionen aus, wie das Wiedererkennen von dir, wenn du auf unsere Website zurückkehrst, und hilft unserem Team zu verstehen, welche Abschnitte der Website für dich am interessantesten und nützlichsten sind.
Latest version of the platform transforms diagnosis of prostate, breast and gastric cancer and includes expanded detection, user-interface, and workflow integration capabilities
Tel Aviv, Israel, September 4, 2022 – Ibex Medical Analytics, the leader in AI-powered cancer diagnostics, today announced the launch and roll-out of version 3.0, a transformative solution offering new detection capabilities and a broad set of features to support pathologists in the diagnosis of multiple tissue types across various digital pathology workflows. Version3.0 is CE-Marked, approved in additional countries and now generally available to Ibex customers.
Creating a new modality for cancer diagnosis, Ibex’s AI platform is the first and most widely deployed AI technology in pathology and used in routine clinical practice at laboratories, hospitals, and health systems worldwide. It supports pathologists across numerous diagnostic tasks during the review of breast, prostate, and gastric biopsies and helps improve the quality of cancer diagnosis, reduce turnaround time, boost productivity and improve user experience for pathologists. The AI platform demonstrated outstanding outcomes across clinical studies performed in multiple pathology labs and diagnostic workflows1,2,3,4,5.
AI platform incorporates the very latest evolution of Ibex’s AI algorithms for detecting cancer and other clinically relevant features in prostate, breast, and gastric biopsies. To ensure very high accuracy and generalizability, Ibex trained the Deep Learning networks on huge, enriched data sets from laboratories worldwide that were digitized by multiple scanning systems, including rare prostatic malignancies such as intraductal carcinoma, neuroendocrine tumor, colorectal adenocarcinoma, lymphoma, and urothelial carcinoma. It also calculates a Gleason score, tumor size and percentage for each cancer slide, potentially enabling pathologists to save review time and reduce subjectivity.
“With an estimated 1.9 million new cancer cases diagnosed in the United States alone this year, we are excited to bring our new version 3.0 to pathology labs worldwide, providing clinically validated, automated decision-support tools that help pathologists diagnose cancer more rapidly and more accurately to support the high demand,” said Issar Yazbin, Vice President of Product Management at Ibex. “Keeping our customers’ needs central to our research and development, we are proud to deploy version3.0, bringing enhanced detection capabilities, improved user experience, increased interoperability tools and ease of implementation into existing clinical workflows.”
The AI platform features an open API (Application Programming Interface) accelerating interoperability and seamless integration with image management solutions, lab information systems and digital pathology workflow solutions. The Ibex API is already used in multiple collaborations between Ibex and leading digital pathology partners where Ibex’s AI findings are seamlessly integrated to the partners’ solutions. Version 3.0 also includes new customizable reporting modules, enabling every customer site to tailor the slide and case reports according to their own needs.